Dysglycemia/prediabetes and cardiovascular risk factors

Reviews in Cardiovascular Medicine

Volumn 10, Issue 4, 2009, Pages 202-208

  Hanna Moussa, Abdullah ^a   Gardner, Michael J ^a   Romayne Kurukulasuriya, L ^a   Sowers, James R ^a,b  

^a University of Missouri   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

Cardiovascular risk; Dysglycemia; Impaired fasting glucose; Impaired glucose tolerance; Prediabetes

Indexed keywords

ALPHA GLUCOSIDASE INHIBITOR; ANGIOTENSIN 1 RECEPTOR ANTAGONIST; ANTIDIABETIC AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FATTY ACID; GLITAZONE DERIVATIVE; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INSULIN; LISINOPRIL; LOSARTAN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; METFORMIN; NITRIC OXIDE; PLACEBO; RAMIPRIL; REACTIVE OXYGEN METABOLITE; ROSIGLITAZONE; ROSUVASTATIN; SULFONYLUREA; TETRAHYDROLIPSTATIN; TOLBUTAMIDE; TRIACYLGLYCEROL; VALSARTAN;

ABDOMINAL OBESITY; BLOOD PRESSURE REGULATION; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; CYTOKINE PRODUCTION; DIABETES MELLITUS; DIABETOGENESIS; DISEASE ASSOCIATION; GLUCAGON BLOOD LEVEL; HEART INFARCTION; HUMAN; HYPERTENSION; IMPAIRED GLUCOSE TOLERANCE; INSULIN BLOOD LEVEL; INSULIN RESISTANCE; ISCHEMIC HEART DISEASE; LIFESTYLE MODIFICATION; METABOLIC SYNDROME X; MORTALITY; NEUROPATHY; NON INSULIN DEPENDENT DIABETES MELLITUS; PHYSICAL ACTIVITY; POLYNEUROPATHY; PREVALENCE; PROTEINURIA; RETINOPATHY; REVIEW; RISK REDUCTION; STROKE; THERAPY EFFECT; TRIACYLGLYCEROL BLOOD LEVEL; WEIGHT REDUCTION; CARDIOVASCULAR DISEASE; GLUCOSE BLOOD LEVEL; GLUCOSE INTOLERANCE; HYPERGLYCEMIA; METABOLISM; RISK ASSESSMENT; RISK FACTOR; TREATMENT OUTCOME;

BLOOD GLUCOSE; CARDIOVASCULAR DISEASES; GLUCOSE INTOLERANCE; HUMANS; HYPERGLYCEMIA; HYPOGLYCEMIC AGENTS; INSULIN RESISTANCE; METABOLIC SYNDROME X; PREDIABETIC STATE; PREVALENCE; RISK ASSESSMENT; RISK FACTORS; RISK REDUCTION BEHAVIOR; TREATMENT OUTCOME;

EID: 77649215854     PISSN: 15306550     EISSN: None     Source Type: Journal    
DOI: 10.3909/ricm0474     Document Type: Review

References (26)

1. Twigg SM, Kamp MC, Davis TM, et al. Prediabetes: a position Statement from the Australian Diabetes Society and Australian Diabetes Educators Association. Med J Aust. 2007;186:461-465.
2. Garber AJ, Handelsman Y, Einhorn D, et al. Diagnosis and management of prediabetes in the continuum of hyperglycemia: when do the risks of diabetes begin? A consensus statement from the American College of Endocrinology and the American Association of Clinical Endocrinologists. Endocr Pract. 2008;14:933-946.
3. Eldin WS, Emara M, Shoker A. Prediabetes: a must to recognise disease state. Int J Clin Pract. 2008;62:642-648.
4. Charpentier G, Riveline JP, Dardari D, Varroud-Vial M. Should postprandial hyperglycaemia in prediabetic and type 2 diabetic patients be treated? Drugs. 2006;66:273-286.
5. Tominaga M, Eguchi H, Manaka H, et al. Impaired glucose tolerance is a risk factor for cardiovascular disease, but not impaired fasting glucose. The Funagata Diabetes Study. Diabetes Care. 1999;22:920-924.
6. Bianchi C, Miccoli R, Penno G, Del Prato S. Primary prevention of cardiovascular disease in people with dysglycemia. Diabetes Care. 2008;31(suppl 2):S208-S214.
7. Blake DR, Meigs JB, Muller DC, et al. Impaired glucose tolerance, but not impaired fasting glucose, is associated with increased levels of coronary heart disease risk factors: results from the Baltimore Longitudinal Study on Aging. Diabetes. 2004;53:2095-2100.
8. Singleton JR, Smith AG, Russell JW, Feldman EL. Microvascular complications of impaired glucose tolerance. Diabetes. 2003;52:2867-2873.
9. Ziegler D, Rathmann W, Dickhaus T et al; for the KORA Study Group. Prevalence of polyneuropathy in pre-diabetes and diabetes is associated with abdominal obesity and macroangiopathy: the MONICA/KORA Augsburg Surveys S2 and S3. Diabetes Care. 2008;31: 464-469.
10. Diabetes Prevention Program Research Group. The prevalence of retinopathy in impaired glucose tolerance and recent-onset diabetes in the Diabetes Prevention Program. Diabet Med. 2007;24:137-144.
11. Haffner SM. Pre-diabetes, insulin resistance, inflammation and CVD risk. Diabetes Res Clin Pract. 2003;61(suppl 1):S9-S18.
12. Dagogo-Jack S. Primary prevention of cardiovascular disease in pre-diabetes: the glass is half full and half empty. Diabetes Care. 2005;28: 971-972.
13. Grundy SM. Metabolic syndrome: connecting and reconciling cardiovascular and diabetes worlds. J Am Coll Cardiol. 2006;47:1093-1100.
14. Haffner SM. Insulin resistance, inflammation, and the prediabetic state. Am J Cardiol. 2003;92:18J-26J.
15. Cubbon R, Kahn M, Kearney MT. Secondary prevention of cardiovascular disease in type 2 diabetes and prediabetes: a cardiologist's perspective. Int J Clin Pract. 2008;62: 287-299.
16. Haffner S. Diabetes and the metabolic syndrome - when is it best to intervene to prevent? Atheroscler Suppl. 2006;7:3-10.
17. Deedwania PC, Fonseca VA. Diabetes, prediabetes, and cardiovascular risk: shifting the paradigm. Am J Med. 2005;118:939-947.
18. Knowler WC, Barrett-Connor E, Fowler SE, et al; for the Diabetes Prevention Program Research Group. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med. 2002;346:393-403.
19. Lindström J, Louheranta A, Mannelin M, et al. The Finnish Diabetes Prevention Study (DPS): Lifestyle intervention and 3-year results on diet and physical activity. Diabetes Care. 2003; 26:3230-3236.
20. Hanefeld M. Cardiovascular benefits and safety profile of acarbose therapy in prediabetes and established type 2 diabetes. Cardiovasc Diabetol. 2007;6:20.
21. Hanefeld M, Chiasson JL, Koehler C, et al. Acarbose slows progression of intima-media thickness of the carotid arteries in subjects with impaired glucose tolerance. Stroke. 2004;35: 1073-1078.
22. DREAM Trial Investigators, Bosch J, Yusuf S, et al. Effect of ramipril on the incidence of diabetes. N Engl J Med. 2006;355:1551-1562.
23. Freeman DJ, Norrie J, Sattar N, et al. Pravastatin and the development of diabetes mellitus: evidence for a protective treatment effect in the West of Scotland Coronary Prevention Study. Circulation. 2001;103:357-362.
24. Jick SS, Bradbury BD. Statins and newly diagnosed diabetes. Br J Clin Pharmacol. 2004;58:303-309.
25. Ridker PM, Danielson E, Fonseca FA, et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med. 2008;359:2195-2207.
26. National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation. 2002;106:3143-3421.